FDA label e6729429-da60-85d8-e053-2a95a90a2abc
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- cd65aa65-94d0-4e88-8af3-20f692432644
- SPL ID
- e6729429-da60-85d8-e053-2a95a90a2abc
- Version
- 27
- Effective date
- 2022-08-17
- Source export date
- 2026-11-13
- Source partition
- 1
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/4245fd4310917b72c4a58c789d30a0b365e492ef46f48e107e3c3e16139b0499/drug-label-0001-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:23:15
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | e6729429-da60-85d8-e053-2a95a90a2abc | id | |
| spl set id | cd65aa65-94d0-4e88-8af3-20f692432644 | set_id |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior s in pediatric and young adult patients in short-term studies . Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )]. Lexapro is not approved for use in pediatric patients less than 12 years of age [ s ee Use in Specific Populations ( 8.4 )]. WARNING: SUICIDAL THOUGHTS AN D BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Lexapro is not approved for use in pediatric patients less than 12 years of age ( 8.4 ).
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS Serotonin Syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs, including Lexapro, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John’s Wort). If such symptoms occur, discontinue Lexapro and initiate supportive treatment. If concomitant use of Lexapro with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases ( 4 , 5.2 ). Discontinuation of Treatment with Lexapro: A gradual reduction in dose rather than abrupt cessation is recommended whenever possible ( 5.3 ). Seizures: Prescribe with care in patients with a history of seizure ( 5.4 ). Activation of Mania/Hypomania: Screen patients for bipolar disorder. ( 5.5 ). Hyponatremia: Can occur in association with SIADH ( 5.6 ) Abnormal Bleeding: Use caution in concomitant use with NSAIDs, aspirin, warfarin or other drugs that affect coagulation ( 5.7 ). Interference with Cognitive and Motor Performance: Use caution when operating machinery ( 5.8 ). Angle Closure Glaucoma: Angle closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants. ( 5.9 ) Use in Patients with Concomitant Illness: Use caution in patients with diseases or conditions that produce altered metabolism or hemodynamic responses ( 5.10 ). Sexual Dysfunction: Lexapro may cause symptoms of sexual dysfunction ( 5.11 ) 5.1 Suicidal Thoughts and Behaviors in Adolescents and Young Adults In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in the antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 1. Table 1: Risk Differences of the Number of Patients of Suicidal Thoughts and Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients Age Range Drug-Placebo Difference in Number of Patients of Suicidal Thoughts and Behaviors per 1000 Patients Treated Increases Compared to Placebo <18 years old 14 additional patients 18 to 24 years old 5 additional patients Decreases Compared to Placebo 25 to 64 years old 1 fewer patient ≥65 years old 6 fewer patients It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression and that depression itself is a risk factor for suicidal thoughts and behaviors. Monitor all antidepressant-treated patients for any indication for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing Lexapro, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors. 5.2 Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including Lexapro, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination) seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome. The concomitant use of Lexapro with MAOIs intended to treat psychiatric disorders is contraindicated. Lexapro should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking Lexapro. Lexapro should be discontinued before initiating treatment with the MAOI [see Contraindications ( 4.1 ) and Dosage and Administration ( 2.5 and 2.6 )]. If concomitant use of Lexapro with other serotonergic drugs including, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, amphetamine and St. John’s Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. Treatment with Lexapro and any concomitant serotonergic agents, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated. 5.3 Discontinuation of Treatment with Lexapro During marketing of Lexapro and other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored for these symptoms when discontinuing treatment with Lexapro. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate [ see Dosage and Administration ( 2.4 ) ]. 5.4 Seizures Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Lexapro has not been systematically evaluated in patients with a seizure disorder. These patients were excluded from clinical studies during the product's premarketing testing. In clinical trials of Lexapro, cases of convulsion have been reported in association with Lexapro treatment. Like other drugs effective in the treatment of major depressive disorder, Lexapro should be introduced with care in patients with a history of seizure disorder. 5.5 Activation of Mania or Hypomania In patients with bipolar disorder, treating a depressive episode with Lexapro or another antidepressant may precipitate a mixed/manic episode. In placebo-controlled trials of Lexapro in major depressive disorder, activation of mania/hypomania was reported in one (0.1%) of 715 patients treated with Lexapro and in none of the 592 patients treated with placebo. One additional case of hypomania has been reported in association with Lexapro treatment. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorders treated with racemic citalopram and other marketed drugs effective in the treatment of major depressive disorder. Prior to initiating treatment with Lexapro, screen patients for any personal or family history of bipolar disorder, mania, or hypomania [see Dosage and Administration ( 2.3 )]. 5.6 Hyponatremia Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including Lexapro. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH), and was reversible when Lexapro was discontinued. Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [ see Geriatric Use ( 8.5 )]. Discontinuation of Lexapro should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. 5.7 Abnormal Bleeding SSRIs and SNRIs, including Lexapro, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal antiinflammatory drugs, warfarin, and other anticoagulants may add to the risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to SSRIs and SNRIs use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Lexapro and NSAIDs, aspirin, or other drugs that affect coagulation. 5.8 Interference with Cognitive and Motor Performance In a study in normal volunteers, Lexapro 10 mg/day did not produce impairment of intellectual function or psychomotor performance. Because any psychoactive drug may impair judgment, thinking, or motor skills, however, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Lexapro therapy does not affect their ability to engage in such activities. 5.9 Angle Closure Glaucoma Angle Closure Glaucoma: The pupillary dilation that occurs following use of many antidepressant drugs including Lexapro may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. 5.10 Use in Patients with Concomitant Illness Clinical experience with Lexapro in patients with certain concomitant systemic illnesses is limited. Caution is advisable in using Lexapro in patients with diseases or conditions that produce altered metabolism or hemodynamic responses. Lexapro has not been systematically evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were generally excluded from clinical studies during the product's premarketing testing. In subjects with hepatic impairment, clearance of racemic citalopram was decreased and plasma concentrations were increased. The recommended dose of Lexapro in hepatically impaired patients is 10 mg/day [ see Dosage and Administration ( 2.3 ) ]. Because escitalopram is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. Until adequate numbers of patients with severe renal impairment have been evaluated during chronic treatment with Lexapro, however, it should be used with caution in such patients [ see Dosage and Administration ( 2.3 ) ]. 5.11 Sexual Dysfunction Use of SSRIs, including Lexapro, may cause symptoms of sexual dysfunction [see Adverse Reactions ( 6.1 )]. In male patients, SSRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SSRI use may result in decreased libido and delayed or absent orgasm. It is important for prescribers to inquire about sexual function prior to initiation of Lexapro and to inquire specifically about changes in sexual function during treatment, because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtaining a detailed history (including timing of symptom onset) is important because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment.
warnings and cautions table
<table><caption>Table 1: Risk Differences of the Number of Patients of Suicidal Thoughts and Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients</caption><col width="144"/><col width="272"/><tbody><tr><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">Age Range</content></td><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">Drug-Placebo Difference in Number of </content><content styleCode="bold">Patients of Suicidal Thoughts and Behaviors </content><content styleCode="bold">per 1000 Patients Treated</content></td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule "/><td align="center" styleCode="Toprule Lrule Rrule ">Increases Compared to Placebo</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule "><18 years old</td><td align="center" styleCode="Toprule Lrule Rrule ">14 additional patients</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">18 to 24 years old</td><td align="center" styleCode="Toprule Lrule Rrule ">5 additional patients</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule "/><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">Decreases Compared to Placebo</content></td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">25 to 64 years old</td><td align="center" styleCode="Toprule Lrule Rrule ">1 fewer patient</td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule ">≥65 years old</td><td align="center" styleCode="Toprule Lrule Rrule ">6 fewer patients</td></tr></tbody></table>
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions table
<table><col width="168"/><col width="154"/><col width="158"/><tbody><tr><td colspan="3" align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">TABLE 5</content></td></tr><tr><td colspan="3" align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">Incidence of Sexual Side Effects in Placebo-Controlled Clinical Trials</content></td></tr><tr><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">Adverse Event</content></td><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">Lexapro</content></td><td align="center" styleCode="Toprule Lrule Rrule "><content styleCode="bold">Placebo</content></td></tr><tr><td styleCode="Lrule Rrule "/><td colspan="2" align="center" styleCode="Toprule Lrule Rrule ">In Males Only</td></tr><tr><td align="center" styleCode="Lrule Rrule "/><td align="center" styleCode="Toprule Lrule Rrule ">(N=407)</td><td align="center" styleCode="Toprule Lrule Rrule ">(N=383)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Ejaculation Disorder (primarily ejaculatory delay) </td><td align="center" styleCode="Toprule Lrule Rrule ">12%</td><td align="center" styleCode="Toprule Lrule Rrule ">1%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Libido Decreased </td><td align="center" styleCode="Toprule Lrule Rrule ">6%</td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td></tr><tr><td styleCode="Toprule Lrule Rrule "> Impotence </td><td align="center" styleCode="Toprule Lrule Rrule ">2%</td><td align="center" styleCode="Toprule Lrule Rrule "><1%</td></tr><tr><td styleCode="Toprule Lrule Rrule "/><td colspan="2" align="center" styleCode="Toprule Lrule Rrule ">In Females Only</td></tr><tr><td styleCode="Toprule Lrule Rrule "/><td align="center" styleCode="Toprule Lrule Rrule ">(N=737)</td><td align="center" styleCode="Toprule Lrule Rrule ">(N=636)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Libido Decreased </td><td align="center" styleCode="Toprule Lrule Rrule ">3%</td><td align="center" styleCode="Toprule Lrule Rrule ">1%</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Anorgasmia </td><td align="center" styleCode="Toprule Lrule Rrule ">3%</td><td align="center" styleCode="Toprule Lrule Rrule "><1%</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.